rss Posted April 1, 2021 Report Share Posted April 1, 2021 Case Rep Dermatol. 2021 Feb 16;13(1):121-128. doi: 10.1159/000511984. eCollection 2021 Jan-Apr. ABSTRACT We present 2 cases of rosacea that were successfully managed with off-label treatment. The first is a case of painful, exuding papulopustular lesions of the nose treated with rifaximin, and the other is a case of severe, debilitating and painful flushing treated with sumatriptan. The cases support previous notions that gastrointestinal comorbidities may be related to papulopustular lesions and that flushing may be related to neurogenic inflammation and migraine. The cases also imply that a new approach to rosacea management, based on endotypes and comorbidities, may be warranted. "Interestingly, infusion of CGRP in patients with migraine induces flushing and can trigger migraine attacks. The anti-migraine drug sumatriptan has been found to block release of CGRP, which may explain the effect in the presented case." PMID:33790755 | PMC:PMC7989675 | DOI:10.1159/000511984 {url} = URL to article • Full Text Sumatriptan has been added to the list of prescription treatments for flushing avoidance Link to comment Share on other sites More sharing options...
Recommended Posts
Create an account or sign in to comment
You need to be a member in order to leave a comment
Create an account
Sign up for a new account in our community. It's easy!
Register a new accountSign in
Already have an account? Sign in here.
Sign In Now